We are contrasting Neuralstem Inc. (NASDAQ:CUR) and Athersys Inc. (NASDAQ:ATHX) on their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuralstem Inc.	N/A	18.92	7.92M	-0.52	0.00
Athersys Inc.	23.95M	9.00	26.06M	-0.21	0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Neuralstem Inc. and Athersys Inc.

Profitability

Table 2 shows Neuralstem Inc. and Athersys Inc.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Neuralstem Inc.	0.00%	-123.1%	-74.7%
Athersys Inc.	-108.81%	-58.7%	-44.6%

Volatility & Risk

A 2.62 beta indicates that Neuralstem Inc. is 162.00% more volatile compared to Standard and Poor’s 500. Athersys Inc. on the other hand, has 0.47 beta which makes it 53.00% less volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio of Neuralstem Inc. is 5.5 while its Quick Ratio stands at 5.5. The Current Ratio of rival Athersys Inc. is 4.6 and its Quick Ratio is has 4.6. Neuralstem Inc. is better equipped to clear short and long-term obligations than Athersys Inc.

Insider and Institutional Ownership

The shares of both Neuralstem Inc. and Athersys Inc. are owned by institutional investors at 16.8% and 23.7% respectively. About 13.52% of Neuralstem Inc.’s share are owned by insiders. Comparatively, insiders own roughly 2.1% of Athersys Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Neuralstem Inc.	6.47%	16.4%	0.1%	-58.3%	-66.18%	59.85%
Athersys Inc.	1.97%	-2.52%	-19.69%	-22.89%	15.67%	7.64%

For the past year Neuralstem Inc.’s stock price has bigger growth than Athersys Inc.

Summary

Neuralstem Inc. beats Athersys Inc. on 5 of the 9 factors.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companyÂ’s stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The companyÂ’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. The company has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.